Cargando…

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease

OBJECTIVES: To characterize patients with Parkinson’s disease (PD) who initiated dopamine agonist (DA) monotherapy, describe medication utilization and provider types, and estimate medication adherence and discontinuation rates. METHODS: Retrospective study identified patients with PD in the Optum R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frazer, Monica, Arcona, Steve, Le, Lisa, Sasane, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842678/ https://www.ncbi.nlm.nih.gov/pubmed/36660109 http://dx.doi.org/10.1016/j.prdoa.2022.100173

Ejemplares similares

An assessment of Parkinson’s disease medication treatment patterns in the Medicaid population
por: Johnsrud, Michael, et al.
Publicado: (2021)

Levodopa treatment patterns in Parkinson’s disease: A retrospective chart review
por: Navaratnam, Prakash, et al.
Publicado: (2022)

Natural history and patterns of treatment change in Parkinson’s disease: A retrospective chart review
por: Navaratnam, Prakash, et al.
Publicado: (2021)

Work Loss and Direct and Indirect Costs Associated with Parkinson’s Disease
por: Jerry, Michelle, et al.
Publicado: (2023)

Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson’s Disease
por: Song, Yan, et al.
Publicado: (2023)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
por: Mohammad, Mohammad Edrees, et al.
Publicado: (2021)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease
por: Zhang, Li-Min, et al.
Publicado: (2015)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report
por: EMEKLİ, Ahmed Serkan, et al.
Publicado: (2019)

Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis
por: Thorlund, Kristian, et al.
Publicado: (2014)

Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation
por: Bandettini di Poggio, Monica, et al.
Publicado: (2013)

Prevalence of hypersexual behavior in Parkinson’s disease patients: Not restricted to males and dopamine agonist use
por: Cooper, Christine A, et al.
Publicado: (2009)

No Dopamine Agonist Modulation of Brain [(18)F]FEOBV Binding in Parkinson’s Disease
por: Albin, Roger L., et al.
Publicado: (2022)

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Compulsive Drumming Induced by Dopamine Agonists in Parkinson’s Disease: Another Aspect of Punding
por: Vitale, Carmine, et al.
Publicado: (2013)

Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups
por: Zhou, Huanxue, et al.
Publicado: (2016)

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
por: Lewis, Mechelle M., et al.
Publicado: (2023)

Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case–control study
por: Arbouw, Maurits E. L., et al.
Publicado: (2011)

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
por: Ecker, Daniel, et al.
Publicado: (2009)

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson’s disease
por: van der Vegt, Joyce P.M., et al.
Publicado: (2020)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease
por: Gungabissoon, Usha, et al.
Publicado: (2020)

Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients
por: Politis, Marios, et al.
Publicado: (2017)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
por: Kim, Jong-Min, et al.
Publicado: (2015)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease
por: Biondetti, Emma, et al.
Publicado: (2021)

Dopamine Receptors and Parkinson's Disease
por: Hisahara, Shin, et al.
Publicado: (2011)

The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study
por: Pellicano, Clelia, et al.
Publicado: (2013)

Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology
por: Borovac, Josip Anđelo
Publicado: (2016)

Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson’s Disease Patients: A Meta-Analysis of Randomized Controlled Trials
por: De Vecchis, Renato, et al.
Publicado: (2016)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Predictors of dopamine dysregulation syndrome in patients with early Parkinson’s disease
por: Liang, Keke, et al.
Publicado: (2023)

Intracerebroventricular dopamine for Parkinson's disease
por: Devos, David, et al.
Publicado: (2017)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1njmvmtm86f84nc0giem2hhvfq